Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by waves1on Aug 25, 2022 1:55pm
138 Views
Post# 34920399

AGN as National Inflation Association's #1 stock

AGN as National Inflation Association's #1 stock
National Inflation Association announced Algernon Pharmaceuticals ($AGN.c $AGNPF)  as its #1 favorite biotechnology stock suggestion! 
 
NIA highlighted that AGN's largest shareholder is Alpha North Asset Management who increased its stake in AGN to 13% earlier this week and that AGN is preparing to launch a Phase I study of DMT for the treatment of stroke.
 
Alpha North increased its stake following the recent share price weakness as it provided a great opportunity to increase its position with CEO Steve Palmer stating "Our increased investment confirms our support for the drug pipeline they are developing as well as our strong belief in management"
 
https://inflation.us/content/nias-1-favorite-biotech-stock-suggestion-agn
<< Previous
Bullboard Posts
Next >>